AK HB195

Prohibits the Alaska Board of Pharmacy and department from requiring fees, approval, or otherwise regulating collaborative practice agreements between pharmacists and other practitioners

Requires pharmacist license applicants and those seeking license transfer through reciprocity to receive education in pain management and opioid use and addiction, unless they do not hold a DEA registration number

Mandates at least 2 hours of continuing education in pain management and opioid use and addiction per licensing period, with exemptions available for pharmacists whose practice does not involve opioids

Expands pharmacist authority to independently provide patient care services for minor conditions, including those requiring a new diagnosis when using CLIA-waived tests, but prohibits prescribing Schedule I or II controlled substances except for opioid use disorder treatment in clinics

Effective date: January 1, 2027